Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 30, 2012. The report details a specific corporate action regarding the repurchase of the company's own shares in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on share repurchase activity and capital structure metrics:
- Shares Purchased: 1,000,000 Ordinary Shares of 25 pence each.
- Purchase Date: October 30, 2012.
- Price Range: Highest price paid was 1,425 pence per share; lowest price paid was 1,410 pence per share.
- Treasury Holdings (Settled): 515,290,427 shares (9.46% of total issued share capital).
- Treasury Holdings (Including Unsettled): 518,290,427 shares (10.51% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,930,044,167 shares.
Material Changes
The material change reported is the reduction of outstanding shares through the purchase of 1,000,000 shares on October 30, 2012. Consequently, the total number of shares held in Treasury increased, raising the percentage of total voting rights held in Treasury to 10.51% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules. The text explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (4,930,044,167) for calculating disclosure thresholds under FSA rules.
- Confirm the updated Treasury share count (518,290,427 including unsettled) to assess the impact on total voting rights.
- Review the price paid (1,410-1,425 pence) against the market price on October 30, 2012, to evaluate the cost efficiency of the buyback.
- Note that this filing does not contain operational or financial performance data; refer to the most recent Form 20-F or interim results for those metrics.